全文获取类型
收费全文 | 4039篇 |
免费 | 272篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 32篇 |
儿科学 | 136篇 |
妇产科学 | 80篇 |
基础医学 | 605篇 |
口腔科学 | 43篇 |
临床医学 | 524篇 |
内科学 | 751篇 |
皮肤病学 | 48篇 |
神经病学 | 396篇 |
特种医学 | 60篇 |
外科学 | 490篇 |
综合类 | 27篇 |
一般理论 | 6篇 |
预防医学 | 473篇 |
眼科学 | 120篇 |
药学 | 272篇 |
中国医学 | 11篇 |
肿瘤学 | 249篇 |
出版年
2024年 | 9篇 |
2023年 | 23篇 |
2022年 | 77篇 |
2021年 | 114篇 |
2020年 | 68篇 |
2019年 | 98篇 |
2018年 | 107篇 |
2017年 | 71篇 |
2016年 | 89篇 |
2015年 | 107篇 |
2014年 | 129篇 |
2013年 | 188篇 |
2012年 | 322篇 |
2011年 | 315篇 |
2010年 | 145篇 |
2009年 | 156篇 |
2008年 | 295篇 |
2007年 | 302篇 |
2006年 | 271篇 |
2005年 | 293篇 |
2004年 | 245篇 |
2003年 | 208篇 |
2002年 | 207篇 |
2001年 | 28篇 |
2000年 | 26篇 |
1999年 | 33篇 |
1998年 | 45篇 |
1997年 | 26篇 |
1996年 | 30篇 |
1995年 | 27篇 |
1994年 | 15篇 |
1993年 | 19篇 |
1992年 | 15篇 |
1991年 | 21篇 |
1990年 | 12篇 |
1989年 | 7篇 |
1987年 | 9篇 |
1986年 | 8篇 |
1985年 | 5篇 |
1984年 | 9篇 |
1983年 | 6篇 |
1982年 | 12篇 |
1981年 | 10篇 |
1980年 | 8篇 |
1979年 | 8篇 |
1978年 | 5篇 |
1977年 | 6篇 |
1965年 | 5篇 |
1961年 | 5篇 |
1930年 | 4篇 |
排序方式: 共有4323条查询结果,搜索用时 406 毫秒
101.
102.
Günthert AR Gründker C Olota A Läsche J Eicke N Emons G 《European journal of endocrinology / European Federation of Endocrine Societies》2005,153(4):613-625
About 50-64% of human breast cancers express receptors for GnRH-I. Direct antiproliferative effects of analogs of GnRH-I on human breast cancer cell lines have been shown. They are at least in part mediated by antagonizing growth promoting effects of estradiol, epidermal growth factor (EGF) or insulin-like growth factor. Recently, expression of a putative receptor for GnRH-II in human tissues was demonstrated. Antiproliferative effects of GnRH-II in human endometrial and ovarian cancer cells were shown not to be mediated through the GnRH-I receptor. Now we demonstrate direct anti-proliferative effects of the GnRH-I analog Triptorelin and the GnRH-II analog [d-Lys(6)]GnRH-II in MCF-7 and T47D human breast cancer cells expressing GnRH-I receptors and putative GnRH-II receptors. Pretreatment with Triptorelin or [d-Lys(6)]GnRH-II blocked EGF-induced autophosphoryla-tion of EGF receptor and activation of mitogen-activated protein kinase (extracellular-signal-regulated kinase 1/2 (ERK1/2)) in these cells. In sublines of MCF-7 and T47D cells, which were developed to be resistant to 4OH-tamoxifen, HER-2/p185 was overexpressed. Pretreatment of these cell lines with Triptorelin or [d-Lys(6)]GnRH-II completely abolished resistance to 4OH-tamoxifen, assessed by 4OH-tamoxifen-induced apoptosis. Analogs of GnRH-I and GnRH-II counteract EGF-dependent signal transduction in human breast cancer cells with expression of receptors for GnRH-I and GnRH-II. Through this mechanism, they probably reverse acquired resistance to 4OH-tamoxifen mediated through overexpression or activation of receptors of the c-erbB family. 相似文献
103.
Tissues of MSH2-deficient mice demonstrate hypermutability on exposure to a DNA methylating agent
下载免费PDF全文
![点击此处可从《Proceedings of the National Academy of Sciences of the United States of America》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Susan E. Andrew Margaret McKinnon Benjamin S. Cheng Agnes Francis Janice Penney Armin H. Reitmair Tak W. Mak Frank R. Jirik 《Proceedings of the National Academy of Sciences of the United States of America》1998,95(3):1126-1130
The mutational response of mismatch repair-deficient animals to the alkylating agent N-methyl-N-nitrosourea was evaluated by using a transgenic lacI reporter system. Although the mutations detected in MSH2 heterozygotes were similar to those of controls, MSH2−/− animals demonstrated striking increases in mutation frequency in response to this agent. G:C to A:T transitions at GpG sites, as opposed to CpG sites, dominated the mutational spectrum of both MSH2+/+ and MSH2−/− N-methyl-N-nitrosourea -treated animals. Extrapolating to humans with hereditary non-polyposis colorectal cancer, the results suggest that MSH2 heterozygotes are unlikely to be at increased risk of mutation, even when exposed to potent DNA methylating agents. In contrast, mismatch repair-deficient cells spontaneously arising within individuals with hereditary non-polyposis colorectal cancer would likely exhibit hypermutability in response to such mutagens, an outcome predicted to accelerate the pace of tumorigenesis. 相似文献
104.
Satish Gopal N George Liomba Nathan D Montgomery Agnes Moses Bongani Kaimila Richard Nyasosela Maria Chikasema Bal M Dhungel Coxcilly Kampani Marcia K Sanders Robert Krysiak Dirk P Dittmer Yuri Fedoriw 《Journal of the International AIDS Society》2015,18(1)
Introduction
Clinical reports of multicentric Castleman disease (MCD) from sub-Saharan Africa (SSA) are scarce despite high prevalence of HIV and Kaposi sarcoma-associated herpesvirus (KSHV). Our objective is to describe characteristics and survival for HIV-associated MCD patients in Malawi. To our knowledge, this is the first HIV-associated MCD case series from the region.Methods
We describe HIV-positive patients with MCD in Lilongwe, and compare them to HIV-associated lymph node Kaposi sarcoma (KS) and non-Hodgkin lymphoma (NHL) patients treated at our centre. All patients were enrolled into a prospective longitudinal cohort study at a national teaching hospital and cancer referral centre serving half of Malawi''s 16 million people. We included adult patients≥18 years of age with HIV-associated MCD (n=6), lymph node KS (n=5) or NHL (n=31) enrolled between 1 June 2013 and 31 January 2015.Results and discussion
MCD patients had a median age of 42.4 years (range 37.2–51.8). All had diffuse lymphadenopathy and five had hepatosplenomegaly. Concurrent KS was present for one MCD patient, and four had performance status ≥3. MCD patients had lower median haemoglobin (6.4 g/dL, range 3.6–9.3) than KS (11.0 g/dL, range 9.1–12.0, p=0.011) or NHL (11.2 g/dL, range 4.5–15.1, p=0.0007). Median serum albumin was also lower for MCD (2.1 g/dL, range 1.7–3.2) than KS (3.7 g/dL, range 3.2–3.9, p=0.013) or NHL (3.4 g/dL, range 1.8–4.8, p=0.003). All six MCD patients were on antiretroviral therapy (ART) with median CD4 count 208 cells/µL (range 108–1146), and all with HIV RNA <400 copies/mL. Most KS and NHL patients were also on ART, although ART duration was longer for MCD (56.4 months, range 18.2–105.3) than KS (14.2 months, range 6.8–21.9, p=0.039) or NHL (13.8 months, range 0.2–98.8, p=0.017). Survival was poorer for MCD patients than lymph node KS or NHL.Conclusions
HIV-associated MCD occurs in Malawi, is diagnosed late and is associated with high mortality. Improvements in awareness, diagnostic facilities, treatment and supportive care are needed to address this likely under-recognized public health problem in SSA. 相似文献105.
van't Veer T Meester H Poenaru D Kogei A Augenstein K Bransford R 《Tropical doctor》2008,38(3):160-162
Spina bifida (SB) affects children worldwide. Studies from developed nations have explored the impact of SB on the quality of life of children and their parents. However, there are no such studies available from developing countries. We have therefore undertaken to document the impact of the disability on the families of affected children in Kenya. A questionnaire was administered to 40 mothers and their children, who were receiving treatment for SB at our institution. The results of this study should indicate where community and governmental resources and educational efforts for the disabled should be directed. 相似文献
106.
Release of cardiac bio-markers during high mechanical index contrast-enhanced echocardiography in humans. 总被引:1,自引:1,他引:1
David Vancraeynest Joelle Kefer Claude Hanet Catherine Fillee Christophe Beauloye Agnes Pasquet Bernhard L Gerber Marianne Philippe Jean-Louis J Vanoverschelde 《European heart journal》2007,28(10):1236-1241
BACKGROUND: Recent experimental data have shown that the combined exposure of rodent hearts to high acoustic pressure and ultrasound contrast agents can induce vascular injury and cell damage. The aim of the present work was to test whether similar effects can be observed in humans. METHODS AND RESULTS: Twenty patients underwent simultaneous arterial and coronary sinus blood sampling during contrast-enhanced echocardiography using Perfluorocarbon-enhanced Sonicated Dextrose Albumin. Control subjects were compared to groups of patients exposed to either high mechanical index (MI = 1.5) triggered second harmonic (1.3-2.6 MHz) imaging or low mechanical index (MI = 0.2) real-time power modulation imaging for 15 min. No significant changes arterio-venous differences in lactate, total creatine kinase (CK) and myoglobin occurred over time in the three groups. Similarly, the arterio-venous difference in CK-MB and troponin I remained stable over time in control and low-MI patients. By contrast, these two parameters progressively increased over time in the high-MI group (P < 0.05 vs. baseline and vs. controls). CONCLUSION: Our data suggest that high-MI contrast-enhanced echocardiography can cause subclinical release of cardiac bio-markers in humans, while low-MI real-time imaging appears to be safer. 相似文献
107.
Lim Pascal; Monin Jean Luc; Monchi Mehran; Garot Jerome; Pasquet Agnes; Hittinger Luc; Vanoverschelde Jean Louis; Carayon Alain; Gueret Pascal 《European heart journal》2005,26(4):419
Regrettably, on 相似文献
108.
Expression of CD7, ELA-2, PR-3, and the polycomb group gene BMI-1 reflects the intrinsic heterogeneity and predicts prognosis of patients with chronic myeloid leukemia (CML) who were not treated with allogeneic stem cell transplantation (allo-SCT). This study investigated whether expression of these genes determined outcome following allo-SCT in a cohort of 84 patients with chronic-phase (CP) CML. We found that patients expressing BMI-1 at a "high" level before allo-SCT had an improved overall survival (P = .005) related to a reduced transplantation-related mortality. In multivariate analysis, when adjusted for the European Group for Blood and Marrow Transplantation (EBMT)-Gratwohl score and other prog-nostic factors, there was an independent association between BMI-1 expression and grades 2 to 4 acute graft-versus-host disease (relative risk [RR] = 2.85; 95% confidence interval [CI], 1.3-6.4; P = .011), suggesting that BMI-1 measured prior to allo-SCT can serve as a biomarker for predicting outcome in patients with CP-CML receiving allo-SCT, and may thus contribute to better therapeutic decisions. 相似文献
109.
110.